Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study.

Wisnivesky JP, Smith CB, Packer S, Strauss GM, Lurslurchachai L, Federman A, Halm EA.

BMJ. 2011 Jul 14;343:d4013. doi: 10.1136/bmj.d4013.

2.

Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis.

Malhotra J, Mhango G, Gomez JE, Smith C, Galsky MD, Strauss GM, Wisnivesky JP.

Ann Oncol. 2015 Apr;26(4):768-73. doi: 10.1093/annonc/mdv008. Epub 2015 Jan 18.

PMID:
25600562
3.

Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer.

Williams CD, Gajra A, Ganti AK, Kelley MJ.

Cancer. 2014 Jul 1;120(13):1939-47. doi: 10.1002/cncr.28679. Epub 2014 Mar 25.

4.

Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based study.

Lin ZZ, Shau WY, Shao YY, Yang YY, Kuo RN, Yang JC, Lai MS.

Oncologist. 2012;17(10):1294-302. doi: 10.1634/theoncologist.2012-0082. Epub 2012 Jul 23.

5.

Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.

Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Aupérin A, Le Chevalier T, Stephens RJ, Arriagada R, Higgins JP, Johnson DH, Van Meerbeeck J, Parmar MK, Souhami RL, Bergman B, Douillard JY, Dunant A, Endo C, Girling D, Kato H, Keller SM, Kimura H, Knuuttila A, Kodama K, Komaki R, Kris MG, Lad T, Mineo T, Piantadosi S, Rosell R, Scagliotti G, Seymour LK, Shepherd FA, Sylvester R, Tada H, Tanaka F, Torri V, Waller D, Liang Y; Non‐Small Cell Lung Cancer Collaborative Group.

Cochrane Database Syst Rev. 2015 Mar 2;(3):CD011430. doi: 10.1002/14651858.CD011430. Review.

6.

Chemotherapy for advanced non-small cell lung cancer in the elderly population.

Santos FN, de Castria TB, Cruz MR, Riera R.

Cochrane Database Syst Rev. 2015 Oct 20;(10):CD010463. doi: 10.1002/14651858.CD010463.pub2. Review.

PMID:
26482542
7.

Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).

Tanaka F, Miyahara R, Ohtake Y, Yanagihara K, Fukuse T, Hitomi S, Wada H.

Eur J Cardiothorac Surg. 1998 Sep;14(3):256-62; discussion 263-4.

PMID:
9761434
8.

A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer.

Yamashita Y, Kataoka K, Ishida T, Matsuura M, Seno N, Mukaida H, Miyahara E, Miyata Y, Okita R, Shimizu K, Watari M, Okumichi T, Okada M.

J Thorac Oncol. 2008 Jun;3(6):612-6. doi: 10.1097/JTO.0b013e318174e05e.

9.

Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.

Logan DM, Lochrin CA, Darling G, Eady A, Newman TE, Evans WK.

Cancer Prev Control. 1997 Dec;1(5):366-78.

PMID:
9765759
10.

Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.

Iezzoni LI, Ngo LH, Li D, Roetzheim RG, Drews RE, McCarthy EP.

Arch Phys Med Rehabil. 2008 Apr;89(4):595-601. doi: 10.1016/j.apmr.2007.09.042. Review.

PMID:
18373987
11.

The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.

Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, Usuda J, Kato H.

Ann Thorac Cardiovasc Surg. 2007 Apr;13(2):73-7. Review.

PMID:
17505412
13.

Patterns and Predictors of Chemotherapy Use for Resected Non-Small Cell Lung Cancer.

Rajaram R, Paruch JL, Mohanty S, Holl JL, Bilimoria KY, Ko CY, Winchester DP, Patel JD, DeCamp MM.

Ann Thorac Surg. 2016 Feb;101(2):533-40. doi: 10.1016/j.athoracsur.2015.08.077. Epub 2015 Oct 24.

PMID:
26507427
14.

Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.

Sonett JR, Suntharalingam M, Edelman MJ, Patel AB, Gamliel Z, Doyle A, Hausner P, Krasna M.

Ann Thorac Surg. 2004 Oct;78(4):1200-5; discussion 1206. Review.

PMID:
15464470
15.

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer.

Keller SM, Vangel MG, Adak S, Wagner H, Schiller JH, Herskovic A, Komaki R, Perry MC, Marks RS, Livingston RB, Johnson DH.

Lung Cancer. 2002 Sep;37(3):303-9.

PMID:
12234700
16.

Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience.

Gauthier I, Ding K, Winton T, Shepherd FA, Livingston R, Johnson DH, Rigas JR, Whitehead M, Graham B, Seymour L.

Lung Cancer. 2007 Mar;55(3):357-63. Epub 2006 Dec 1.

PMID:
17141357
17.

Survival after surgery following chemotherapy for non-small-cell lung cancer.

Molnár TF, Balikó Z, Sárosi V, Horváth PO.

Asian Cardiovasc Thorac Ann. 2010 Feb;18(2):141-6. doi: 10.1177/0218492310361271.

PMID:
20304848
18.

Adjuvant chemotherapy for non-small cell lung cancer.

Solomon B, Bunn PA Jr.

Cancer Invest. 2007 Jun;25(4):217-25. Review.

PMID:
17612931
19.

Role of chemotherapy in stages I to III non-small cell lung cancer.

Strauss GM.

Chest. 1999 Dec;116(6 Suppl):509S-516S. Review.

PMID:
10619521
20.

Supplemental Content

Support Center